These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36980931)

  • 21. Identification of an elusive spliceogenic MYBPC3 variant in an otherwise genotype-negative hypertrophic cardiomyopathy pedigree.
    Torrado M; Maneiro E; Lamounier Junior A; Fernández-Burriel M; Sánchez Giralt S; Martínez-Carapeto A; Cazón L; Santiago E; Ochoa JP; McKenna WJ; Santomé L; Monserrat L
    Sci Rep; 2022 May; 12(1):7284. PubMed ID: 35508642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation.
    Adalsteinsdottir B; Teekakirikul P; Maron BJ; Burke MA; Gudbjartsson DF; Holm H; Stefansson K; DePalma SR; Mazaika E; McDonough B; Danielsen R; Seidman JG; Seidman CE; Gunnarsson GT
    Circulation; 2014 Sep; 130(14):1158-67. PubMed ID: 25078086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
    Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
    Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death.
    Teirlinck CH; Senni F; Malti RE; Majoor-Krakauer D; Fellmann F; Millat G; André-Fouët X; Pernot F; Stumpf M; Boutarin J; Bouvagnet P
    BMC Med Genet; 2012 Nov; 13():105. PubMed ID: 23140321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Founder mutation in myosin-binding protein C with an early onset and a high penetrance in males.
    Méndez I; Fernández AI; Espinosa MÁ; Cuenca S; Lorca R; Rodríguez JF; Tamargo M; García-Montero M; Gómez C; Vilches S; Vázquez N; Álvarez R; Medrano C; Yotti R; Fernández-Avilés F; Bermejo J
    Open Heart; 2021 Sep; 8(2):. PubMed ID: 34588271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotypic variations in carriers of predicted protein-truncating genetic variants in MYBPC3: an autopsy-based case series.
    Williams N; Marion R; McDonald TV; Wang D; Zhou B; Eng LS; Um SY; Lin Y; Ruiter K; Rojas L; Sampson BA; Tang Y
    Cardiovasc Pathol; 2018; 37():30-33. PubMed ID: 30282064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The R820W mutation in the MYBPC3 gene, associated with hypertrophic cardiomyopathy in cats, causes hypertrophic cardiomyopathy and left ventricular non-compaction in humans.
    Ripoll Vera T; Monserrat Iglesias L; Hermida Prieto M; Ortiz M; Rodriguez Garcia I; Govea Callizo N; Gómez Navarro C; Rosell Andreo J; Gámez Martínez JM; Pons Lladó G; Cremer Luengos D; Torres Marqués J
    Int J Cardiol; 2010 Nov; 145(2):405-407. PubMed ID: 20542340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Whole MYBPC3 NGS sequencing as a molecular strategy to improve the efficiency of molecular diagnosis of patients with hypertrophic cardiomyopathy.
    Janin A; Chanavat V; Rollat-Farnier PA; Bardel C; Nguyen K; Chevalier P; Eicher JC; Faivre L; Piard J; Albert E; Nony S; Millat G
    Hum Mutat; 2020 Feb; 41(2):465-475. PubMed ID: 31730716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene.
    Lekanne Deprez RH; Muurling-Vlietman JJ; Hruda J; Baars MJ; Wijnaendts LC; Stolte-Dijkstra I; Alders M; van Hagen JM
    J Med Genet; 2006 Oct; 43(10):829-32. PubMed ID: 16679492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
    Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
    J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biallelic mutation in MYH7 and MYBPC3 leads to severe cardiomyopathy with left ventricular noncompaction phenotype.
    Kolokotronis K; Kühnisch J; Klopocki E; Dartsch J; Rost S; Huculak C; Mearini G; Störk S; Carrier L; Klaassen S; Gerull B
    Hum Mutat; 2019 Aug; 40(8):1101-1114. PubMed ID: 30924982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes.
    Jääskeläinen P; Miettinen R; Kärkkäinen P; Toivonen L; Laakso M; Kuusisto J
    Ann Med; 2004; 36(1):23-32. PubMed ID: 15000344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy.
    Helms AS; Tang VT; O'Leary TS; Friedline S; Wauchope M; Arora A; Wasserman AH; Smith ED; Lee LM; Wen XW; Shavit JA; Liu AP; Previs MJ; Day SM
    JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31877118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short communication: the cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic cardiomyopathy.
    Saltzman AJ; Mancini-DiNardo D; Li C; Chung WK; Ho CY; Hurst S; Wynn J; Care M; Hamilton RM; Seidman GW; Gorham J; McDonough B; Sparks E; Seidman JG; Seidman CE; Rehm HL
    Circ Res; 2010 May; 106(9):1549-52. PubMed ID: 20378854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myocardial Deformation Analysis in
    Höller V; Seebacher H; Zach D; Schwegel N; Ablasser K; Kolesnik E; Gollmer J; Waltl G; Rainer PP; Verheyen S; Zirlik A; Verheyen N
    Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myosin-binding Protein C Compound Heterozygous Variant Effect on the Phenotypic Expression of Hypertrophic Cardiomyopathy.
    Rafael JF; Cruz FEDS; Carvalho ACC; Gottlieb I; Cazelli JG; Siciliano AP; Dias GM
    Arq Bras Cardiol; 2017 Apr; 108(4):354-360. PubMed ID: 28538763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defects.
    Wessels MW; Herkert JC; Frohn-Mulder IM; Dalinghaus M; van den Wijngaard A; de Krijger RR; Michels M; de Coo IF; Hoedemaekers YM; Dooijes D
    Eur J Hum Genet; 2015 Jul; 23(7):922-8. PubMed ID: 25335496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of Autophagy Ameliorates Cardiomyopathy in
    Singh SR; Zech ATL; Geertz B; Reischmann-Düsener S; Osinska H; Prondzynski M; Krämer E; Meng Q; Redwood C; van der Velden J; Robbins J; Schlossarek S; Carrier L
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29021349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Description of a Cohort with a New Truncating
    Fernández Suárez N; Viadero Ubierna MT; Garde Basas J; Onecha de la Fuente ME; Amigo Lanza MT; Martin Gorria G; Rivas Pérez A; Ruiz Guerrero L; González-Lamuño D
    Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a novel MYBPC3 gene variant in a patient with hypertrophic cardiomyopathy.
    Brion M; Allegue C; Gil R; Blanco-Verea A; Carracedo A; Pagannone E; Evangelista A; Di Castro S; Marchitti S; Stanzione R; Volpe M; Rubattu S
    Ann Clin Lab Sci; 2010; 40(3):285-9. PubMed ID: 20689143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.